EpiVacCorona Uses, Dosage, Side Effects and more
EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus. It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575).
| Trade Name | EpiVacCorona |
| Generic | EpiVacCorona |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
